Katherine E Tansey

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7019492/publications.pdf

Version: 2024-02-01

61 papers 10,937 citations

36 h-index 106344 65 g-index

71 all docs

71 docs citations

71 times ranked

18418 citing authors

#	Article	IF	CITATIONS
1	Genome-wide association analyses identify 44 risk variants and refine the genetic architecture of major depression. Nature Genetics, 2018, 50, 668-681.	21.4	2,224
2	Functional impact of global rare copy number variation in autism spectrum disorders. Nature, 2010, 466, 368-372.	27.8	1,803
3	A mega-analysis of genome-wide association studies for major depressive disorder. Molecular Psychiatry, 2013, 18, 497-511.	7.9	1,002
4	A genome-wide linkage and association scan reveals novel loci for autism. Nature, 2009, 461, 802-808.	27.8	570
5	Rare and low-frequency coding variants alter human adult height. Nature, 2017, 542, 186-190.	27.8	544
6	A genome-wide scan for common alleles affecting risk for autism. Human Molecular Genetics, 2010, 19, 4072-4082.	2.9	538
7	An Inflammatory Biomarker as a Differential Predictor of Outcome of Depression Treatment With Escitalopram and Nortriptyline. American Journal of Psychiatry, 2014, 171, 1278-1286.	7.2	336
8	Protein-altering variants associated with body mass index implicate pathways that control energy intake and expenditure in obesity. Nature Genetics, 2018, 50, 26-41.	21.4	286
9	Role for the kinase SGK1 in stress, depression, and glucocorticoid effects on hippocampal neurogenesis. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 8708-8713.	7.1	272
10	Interaction between stress and the BDNFVal66Met polymorphism in depression: a systematic review and meta-analysis. BMC Medicine, 2014, 12, 7.	5.5	228
11	Common Genetic Variation and Antidepressant Efficacy in Major Depressive Disorder: A Meta-Analysis of Three Genome-Wide Pharmacogenetic Studies. American Journal of Psychiatry, 2013, 170, 207-217.	7.2	216
12	Association between C-reactive protein (CRP) with depression symptom severity and specific depressive symptoms in major depression. Brain, Behavior, and Immunity, 2017, 62, 344-350.	4.1	202
13	Contribution of Common Genetic Variants to Antidepressant Response. Biological Psychiatry, 2013, 73, 679-682.	1.3	199
14	Phenotypic Manifestation of Genetic Risk for Schizophrenia During Adolescence in the General Population. JAMA Psychiatry, 2016, 73, 221.	11.0	197
15	Genome-wide Association for Major Depression Through Age at Onset Stratification: Major Depressive Disorder Working Group of the Psychiatric Genomics Consortium. Biological Psychiatry, 2017, 81, 325-335.	1.3	175
16	Genetic Predictors of Response to Serotonergic and Noradrenergic Antidepressants in Major Depressive Disorder: A Genome-Wide Analysis of Individual-Level Data and a Meta-Analysis. PLoS Medicine, 2012, 9, e1001326.	8.4	110
17	Evidence of Common Genetic Overlap Between Schizophrenia and Cognition. Schizophrenia Bulletin, 2016, 42, 832-842.	4.3	102
18	Genetic relationships between suicide attempts, suicidal ideation and major psychiatric disorders: A genomeâ€wide association and polygenic scoring study. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2014, 165, 428-437.	1.7	99

#	Article	IF	CITATIONS
19	Multimodal Brain Imaging Reveals Structural Differences in Alzheimer's Disease Polygenic Risk Carriers: A Study in Healthy Young Adults. Biological Psychiatry, 2017, 81, 154-161.	1.3	91
20	Oxytocin receptor (OXTR) does not play a major role in the aetiology of autism: Genetic and molecular studies. Neuroscience Letters, 2010, 474, 163-167.	2.1	90
21	An Analysis of Two Genome-wide Association Meta-analyses Identifies a New Locus for Broad Depression Phenotype. Biological Psychiatry, 2017, 82, 322-329.	1.3	84
22	Genetic risk for Alzheimer's disease is concentrated in specific macrophage and microglial transcriptional networks. Genome Medicine, 2018, 10, 14.	8.2	83
23	The Psychiatric Risk Gene Transcription Factor 4 (TCF4) Regulates Neurodevelopmental Pathways Associated With Schizophrenia, Autism, and Intellectual Disability. Schizophrenia Bulletin, 2018, 44, 1100-1110.	4.3	79
24	Oscillatory hyperactivity and hyperconnectivity in young APOE-É>4 carriers and hypoconnectivity in Alzheimer's disease. ELife, 2019, 8, .	6.0	78
25	Genetic differences in cytochrome P450 enzymes and antidepressant treatment response. Journal of Psychopharmacology, 2014, 28, 133-141.	4.0	75
26	Functionality of promoter microsatellites of arginine vasopressin receptor 1A (AVPR1A): implications for autism. Molecular Autism, 2011, 2, 3.	4.9	71
27	DNA methylation in interleukin-11 predicts clinical response to antidepressants in GENDEP. Translational Psychiatry, 2013, 3, e300-e300.	4.8	71
28	Pharmacogenetics of antidepressant response: A polygenic approach. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2017, 75, 128-134.	4.8	71
29	Tumor necrosis factor and its targets in the inflammatory cytokine pathway are identified as putative transcriptomic biomarkers for escitalopram response. European Neuropsychopharmacology, 2013, 23, 1105-1114.	0.7	68
30	Effect of cytochrome CYP2C19 metabolizing activity on antidepressant response and side effects: Meta-analysis of data from genome-wide association studies. European Neuropsychopharmacology, 2018, 28, 945-954.	0.7	64
31	The Relationship Between Polygenic Risk Scores and Cognition in Schizophrenia. Schizophrenia Bulletin, 2020, 46, 336-344.	4.3	60
32	Formalising recall by genotype as an efficient approach to detailed phenotyping and causal inference. Nature Communications, 2018, 9, 711.	12.8	54
33	Examining cognition across the bipolar/schizophrenia diagnostic spectrum. Journal of Psychiatry and Neuroscience, 2018, 43, 245-253.	2.4	49
34	Biomarkers predicting treatment outcome in depression: what is clinically significant?. Pharmacogenomics, 2012, 13, 233-240.	1.3	44
35	Polygenic Risk of Psychosis and Ventral Striatal Activation During Reward Processing in Healthy Adolescents. JAMA Psychiatry, 2016, 73, 852.	11.0	40
36	Putative Transcriptomic Biomarkers in the Inflammatory Cytokine Pathway Differentiate Major Depressive Disorder Patients from Control Subjects and Bipolar Disorder Patients. PLoS ONE, 2014, 9, e91076.	2.5	39

3

#	Article	IF	CITATIONS
37	FUNCTIONAL POLYMORPHISM IN THE BRAIN-DERIVED NEUROTROPHIC FACTOR GENE INTERACTS WITH STRESSFUL LIFE EVENTS BUT NOT CHILDHOOD MALTREATMENT IN THE ETIOLOGY OF DEPRESSION. Depression and Anxiety, 2014, 31, 326-334.	4.1	37
38	Structural and Functional Neuroimaging of Polygenic Risk for Schizophrenia: A Recall-by-Genotype–Based Approach. Schizophrenia Bulletin, 2019, 45, 405-414.	4.3	35
39	Fractional anisotropy of the uncinate fasciculus and cingulum in bipolar disorder type I, type II, unaffected siblings and healthy controls. British Journal of Psychiatry, 2018, 213, 548-554.	2.8	34
40	Alzheimer's disease risk variant in $\langle i \rangle$ CLU $\langle i \rangle$ is associated with neural inefficiency in healthy individuals. Alzheimer's and Dementia, 2015, 11, 1144-1152.	0.8	33
41	Whole-exome sequencing identifies a polymorphism in the BMP5 gene associated with SSRI treatment response in major depression. Journal of Psychopharmacology, 2013, 27, 915-920.	4.0	31
42	Exploring the role of drug-metabolising enzymes in antidepressant side effects. Psychopharmacology, 2015, 232, 2609-2617.	3.1	31
43	The inflammatory cytokines: molecular biomarkers for major depressive disorder?. Biomarkers in Medicine, 2015, 9, 169-180.	1.4	31
44	Identifying the Common Genetic Basis of Antidepressant Response. Biological Psychiatry Global Open Science, 2022, 2, 115-126.	2.2	31
45	Associations between polygenic risk for schizophrenia and brain function during probabilistic learning in healthy individuals. Human Brain Mapping, 2016, 37, 491-500.	3.6	27
46	Classical Human Leukocyte Antigen Alleles and C4 Haplotypes Are Not Significantly Associated With Depression. Biological Psychiatry, 2020, 87, 419-430.	1.3	27
47	Investigation of blood mRNA biomarkers for suicidality in an independent sample. Translational Psychiatry, 2014, 4, e474-e474.	4.8	24
48	Schizophrenia risk variants modulate white matter volume across the psychosis spectrum: Evidence from two independent cohorts. Neurolmage: Clinical, 2015, 7, 764-770.	2.7	22
49	Convergent Evidence That ZNF804A Is a Regulator of Pre-messenger RNA Processing and Gene Expression. Schizophrenia Bulletin, 2019, 45, 1267-1278.	4.3	22
50	Phenotypic Association Analyses With Copy Number Variation in Recurrent Depressive Disorder. Biological Psychiatry, 2016, 79, 329-336.	1.3	21
51	ATP-binding cassette sub-family F member 1 (ABCF1) is identified as a putative therapeutic target of escitalopram in the inflammatory cytokine pathway. Journal of Psychopharmacology, 2013, 27, 609-615.	4.0	20
52	Copy number variants and therapeutic response to antidepressant medication in major depressive disorder. Pharmacogenomics Journal, 2014, 14, 395-399.	2.0	20
53	Transcriptomics and the mechanisms of antidepressant efficacy. European Neuropsychopharmacology, 2016, 26, 105-112.	0.7	19
54	Polygenic impact of common genetic risk loci for Alzheimer's disease on cerebral blood flow in young individuals. Scientific Reports, 2019, 9, 467.	3.3	19

#	Article	IF	CITATION
55	Enrichment of schizophrenia heritability in both neuronal and glia cell regulatory elements. Translational Psychiatry, 2018, 8, 7.	4.8	18
56	Genetic susceptibility for bipolar disorder and response to antidepressants in major depressive disorder. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2014, 165, 77-83.	1.7	16
57	The genomeâ€wide expression effects of escitalopram and its relationship to neurogenesis, hippocampal volume, and antidepressant response. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2017, 174, 427-434.	1.7	16
58	Association of Whole-Genome and NETRIN1 Signaling Pathway–Derived Polygenic Risk Scores for Major Depressive Disorder and White Matter Microstructure in the UK Biobank. Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, 2019, 4, 91-100.	1.5	16
59	Schizophrenia Genetics: Building the Foundations of the Future. Schizophrenia Bulletin, 2015, 41, 15-19.	4.3	8
60	Lack of association between markers in the ITGA3, ITGAV, ITGA6 and ITGB3 and autism in an Irish sample. Autism Research, 2010, 3, 342-344.	3.8	6
61	Global Brain Flexibility During Working Memory Is Reduced in a High-Genetic-Risk Group for Schizophrenia. Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, 2021, 6, 1176-1184.	1.5	6